Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.

Checkmate Pharmaceuticals (CMPI) News Today

Checkmate Pharmaceuticals logo
Checkmate Pharmaceuticals, Inc. stock logo
Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) Short Interest Update
Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI - Get Rating) was the target of a significant increase in short interest in the month of May. As of May 15th, there was short interest totalling 78,900 shares, an increase of 71.5% from the April 30th total of 46,000 shares. Based on an average daily trading volume, of 202,600 shares, the short-interest ratio is currently 0.4 days. Currently, 1.2% of the company's shares are short sold.
Checkmate Pharmaceuticals, Inc. stock logo
Analysts Expect Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) to Post -$0.75 Earnings Per Share
Brokerages expect that Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI - Get Rating) will report earnings per share (EPS) of ($0.75) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Checkmate Pharmaceuticals' earnings. Checkmate Pharmaceuticals post
Checkmate Pharmaceuticals, Inc. stock logo
-$0.73 EPS Expected for Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) This Quarter
Wall Street brokerages forecast that Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI - Get Rating) will report earnings of ($0.73) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for Checkmate Pharmaceuticals' earnings. Checkmate Pharm
Checkmate Pharmaceuticals, Inc. stock logo
Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) Major Shareholder Global Strategic Fund I. Venbio Sells 47,396 Shares
Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI - Get Rating) major shareholder Global Strategic Fund I. Venbio sold 47,396 shares of the business's stock in a transaction on Wednesday, April 27th. The shares were sold at an average price of $10.38, for a total transaction of $491,970.48. Following the completion of the transaction, the insider now directly owns 2,948,463 shares of the company's stock, valued at approximately $30,605,045.94. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Large shareholders that own 10% or more of a company's stock are required to disclose their transactions with the SEC.
Checkmate Pharmaceuticals Announces CEO Transition
Peek Under The Hood: VTI Has 11% Upside
Checkmate Pharmaceuticals Inc.
Get Checkmate Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for CMPI and its competitors with MarketBeat's FREE daily newsletter.

Did You See Trump’s Bombshell Exec. Order 001? (Ad)

Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."

I put all the details together for you here — but please hurry. 

CMPI Media Mentions By Week

CMPI Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CMPI
News Sentiment

0.00

0.60

Average
Medical
News Sentiment

CMPI News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CMPI Articles
This Week

0

0

CMPI Articles
Average Week

Get Checkmate Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for CMPI and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:CMPI) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners